RIGLRigel Pharmaceuticals, Inc.

The latest analyst update on Rigel Pharmaceuticals centers on a higher assessed fair value, which has moved from US$51.6 to US$61.2 per share in the current model. Analysts link this shift to how they view Veppanu in the U.S. and the ex U.S. potential of Rezlidhia under the Kissei partnership, with both products seen as key to supporting or challenging the new valuation. As you read on, you will see how to track this evolving narrative and what it could mean for your own view of Rigel...

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

VEPPANU launch and R289 data readouts drive second-half priorities.

Moby summary of Rigel Pharmaceuticals, Inc.'s Q2 2026 earnings call

Rigel Pharmaceuticals (NASDAQ:RIGL) reported second-quarter 2026 total revenue of $78.7 million and net income of $17.3 million, while outlining plans to launch newly licensed breast cancer therapy VEPPANU in mid-August. The company generated $67 million in U.S. net product sales during the quarter

Moby summary of Arvinas, Inc.'s Q2 2026 earnings call

Rigel (RIGL) delivered earnings and revenue surprises of -3.30% and +14.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?